The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Among patients with resectable early-stage non-small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide benefit beyond either approach alone. METHODS: We conducted a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab in patients with early-stage NSCLC. Participants with resectable stage II, IIIA, or IIIB (N2 stage) NSCLC were assigned in a 1:1 ratio to receive neoadjuvant pembrolizumab (200 mg) or placebo once every 3 weeks, each of which was given with cisplatin-based chemotherapy for 4 cycles, followed by surgery and adjuvant pembrolizumab (200 mg) or placebo once every 3 weeks for up to 13 cycles. The dual primary end points were event-free survival (the time from randomization to the first occurrence of local progression that precluded the planned surgery, unresectable tumor, progression or recurrence, or death) and overall survival. Secondary end points included major pathological response, pathological complete response, and safety. RESULTS: A total of 397 participants were assigned to the pembrolizumab group, and 400 to the placebo group. At the prespecified first interim analysis, the median follow-up was 25.2 months. Event-free survival at 24 months was 62.4% in the pembrolizumab group and 40.6% in the placebo group (hazard ratio for progression, recurrence, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.72; P<0.001). The estimated 24-month overall survival was 80.9% in the pembrolizumab group and 77.6% in the placebo group (P = 0.02, which did not meet the significance criterion). A major pathological response occurred in 30.2% of the participants in the pembrolizumab group and in 11.0% of those in the placebo group (difference, 19.2 percentage points; 95% CI, 13.9 to 24.7; P<0.0001; threshold, P = 0.0001), and a pathological complete response occurred in 18.1% and 4.0%, respectively (difference, 14.2 percentage points; 95% CI, 10.1 to 18.7; P<0.0001; threshold, P = 0.0001). Across all treatment phases, 44.9% of the participants in the pembrolizumab group and 37.3% of those in the placebo group had treatment-related adverse events of grade 3 or higher, including 1.0% and 0.8%, respectively, who had grade 5 events. CONCLUSIONS: Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery. Overall survival did not differ significantly between the groups in this analysis. (Funded by Merck Sharp and Dohme; KEYNOTE-671 ClinicalTrials.gov number, NCT03425643.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given the lack of successful trials in the perioperative space in HCC, no surrogate end point has been validated yet, as is the case for pCR in patients with NSCLC20,120 and breast cancer8.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [120]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ICI-treatment is approved for the treatment of NSCLC patients in the localized and metastatic setting regardless of PD-L1 status2–4, many patients still fail to achieve clinically meaningful responses.”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since results from one of the first clinical trials of such a therapeutic approach in patients with NSCLC were reported in 2018 (ref. 19), the efficacy and safety of neoadjuvant ICIs have been firmly established in multiple tumour types, with FDA approvals for two indications (NSCLC20,120 and triple-negative breast cancer8).”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [120]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationDurvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationNeoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Self-citationOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationFelip, E., Altorki, N. K., Zhou, C., Csőszi, T., Vynnychenko, I. O., Goloborodko, O., Luft, A. V., Akopov, A. L., Martínez‐Martí, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,497
Self-citationNon–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430
Flagged first, then by citations
Research works printed but not linked: 2
- Brierly JD Gospodarowicz MK Wittekind C. TNM classification of malignant tumors. 8th ed. New York: John Wiley 2016.
- Heymach JV Harpole D Mitsudomi T et al. AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. In: Proceedings and Abstracts of the 114th Annual Meeting of the American Association for Cancer Research April 14–19 2023. Orlando FL: American Association for Cancer Research 2023. abstract.
Cited by
Sorted by citations
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Heymach, J. V., Harpole, D. H., Mitsudomi, T., Taube, J. M., Gálffy, G., Hochmair, M. J., Winder, T. L., Zukov, R. A., Garbaos, G., Gao, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304875 · Cited by 835
Self-citationHendriks, L. E. L., Remón, J., Finn, C. F., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 690
Perioperative Nivolumab in Resectable Lung Cancer
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lü, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311926 · Cited by 574
Self-citationNeoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Uppaluri, R., Haddad, R. I., Tao, Y., Tourneau, C. L., Lee, N. Y., Westra, W. H., Chernock, R. D., Tahara, M., Harrington, K. J., Klochikhin, A. L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415434 · Cited by 473
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Lü, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Neotorch Investigators, Fang, W., Xing, W., Chen, Q., Yang, L., et al. (2024) · JAMA · doi:10.1001/jama.2023.24735 · Cited by 405
Self-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Spicer, J. D., Garassino, M. C., Wakelee, H. A., Liberman, M., Kato, T., Tsuboi, M., Lee, S., Chen, K., Dooms, C., Majem, M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01756-2 · Cited by 328
Self-citationLung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., ŁUKASIEWICZ, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 306
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Forde, P. M., Spicer, J. D., Provencio, M., Mitsudomi, T., Awad, M. M., Wang, C., Lu, S., Felip, E., Swanson, S., Brahmer, J. R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502931 · Cited by 273
Self-citationChang, J. Y., Lin, S. H., Dong, W., Liao, Z. X., Gandhi, S. J., Gay, C. M., Zhang, J. J., Chun, S. G., Elamin, Y. Y., Fossella, F. V., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01384-3 · Cited by 257
Neoadjuvant Chemoimmunotherapy for NSCLC
Sorin, M., Prosty, C. J., Ghaleb, L., Nie, K., Katergi, K., Shahzad, M. H., Dubé, L.-R., Atallah, A., Swaby, A. M., Dankner, M., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.0057 · Cited by 247
Self-citationFekete, J. T., & Győrffy, B. (2025) · Journal of Medical Internet Research · doi:10.2196/64016 · Cited by 248
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 230
Update 2025: Management of Non‑Small-Cell Lung Cancer
Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025) · Lung · doi:10.1007/s00408-025-00801-x · Cited by 229
Mountzios, G., Remón, J., Hendriks, L. E. L., García‐Campelo, R., Rolfo, C. D., Schil, P. E. V., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 212
Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02660-6 · Cited by 198
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Spicer, J. D., Cascone, T., Wynes, M. W., Ahn, M., Đačić, S., Felip, E., Forde, P. M., Higgins, K. A., Kris, M. G., Mitsudomi, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.06.010 · Cited by 179
Self-citationNCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024
Thompson, J. A., Schneider, B. J., Brahmer, J. R., Zaid, M. I. A., Achufusi, A., Armand, P. A., Berkenstock, M., Bermas, B. L., Braaten, T. J., Budde, L. E., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0057 · Cited by 176
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
Liu, Z., Yang, Z., Wu, J., Zhang, W., Sun, Y., Zhang, C., Bai, G., Li, Y., Fan, H., Chen, Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.018 · Cited by 184
Self-citationZer, A., Ahn, M., Barlési, F., Bubendorf, L., Ruysscher, D. D., Garrido, P., Gautschi, O. P., Hendriks, L. E. L., Janne, P. A., Kerr, K. M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.08.003 · Cited by 165
Management of locally advanced non‐small cell lung cancer: State of the art and future directions
Miao, D., Zhao, J., Han, Y., Zhou, J., Li, X., Zhang, T., Li, W., & Xia, Y. (2023) · 癌症：英文版 · doi:10.1002/cac2.12505 · Cited by 165
Recent advances in therapeutic strategies for non-small cell lung cancer
Su, P., Furuya, N., Asrar, A., Rolfo, C. D., Li, Z., Carbone, D. P., & He, K. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01679-1 · Cited by 164
Yue, D., Wang, W., Liu, H., Chen, Q., Chen, C., Liu, L., Zhang, P., Zhao, G., Yang, F., Han, G., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00269-8 · Cited by 155
Cascone, T., Kar, G., Spicer, J. D., García-Campelo, R., Weder, W., Daniel, D. B., Spigel, D. R., Hussein, M., Mazières, J., Oliveira, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0436 · Cited by 142
Self-citationEnfield, K. S. S., Colliver, E., Lee, C., Magness, A., Moore, D. A., Sivakumar, M., Grigoriadis, K., Pich, O., Karasaki, T., Hobson, P. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1380 · Cited by 151
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A.-T., Eggermont, A. M. M., & Galluzzi, L. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 131
Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors
Catanzaro, E., Beltrán‐Visiedo, M., Galluzzi, L., & Krysko, D. V. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01245-8 · Cited by 131
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 114
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
He, J., Tsuboi, M., Weder, W., Chen, K.-N., Hochmair, M. J., Shih, J., Lee, S. Y., Lee, K., Nhung, N. V., Saeteng, S., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00883 · Cited by 117
Self-citationGross, N. D., Miller, D. M., Khushalani, N. I., Divi, V., Ruiz, E. S., Lipson, E. J., Meier, F. E., Su, Y. B., Swiecicki, P. L., Atlas, J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00459-x · Cited by 109
Allaf, M. E., Kim, S.-E., Master, V. A., McDermott, D. F., Harshman, L. C., Cole, S., Drake, C. G., Signoretti, S., Akgül, M., Baniak, N., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00211-0 · Cited by 104
Provencio, M., Nadal, E., Insa, A., Campelo, R. G., Casal, J., Dómine, M., Massutí, B., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00498-4 · Cited by 99
Self-citationNeoadjuvant Chemo-Immunotherapy for Early-Stage Non–Small Cell Lung Cancer
Banna, G. L., Hassan, M. A., Signori, A., Giunta, E. F., Maniam, A., Anpalakhan, S., Acharige, S. M., Ghose, A., & Addeo, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.6837 · Cited by 97
Hines, J. B., Cameron, R. B., Esposito, A., Kim, L., Porcu, L., Nuccio, A., Viscardi, G., Ferrara, R., Veronesi, G., Forde, P. M., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.03.010 · Cited by 96
Schüler, M., Cuppens, K., Plönes, T., Wiesweg, M., Pont, B. D., Hegedűs, B., Köster, J., Mairinger, F. D., Darwiche, K., Paschen, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02965-0 · Cited by 91
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
Lee, J. M., McNamee, C., Toloza, E. M., Negrao, M. V., Lin, J., Shum, E., Cummings, A. L., Kris, M. G., Sepesi, B., Bāra, I., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.006 · Cited by 89
Self-citationAdjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
Liang, Y., Liu, X., Shen, L., Hu, G., Zou, G., Zhang, N., Chen, C., Chen, X., Zhu, X., Yuan, Y., et al. (2025) · JAMA · doi:10.1001/jama.2025.1132 · Cited by 86
Fujiwara, Y., Horita, N., Adib, E., Zhou, S., Nassar, A. H., Asad, Z. U. A., Cortellini, A., & Naqash, A. R. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00524-7 · Cited by 88
Blakely, C. M., Urisman, A., Gubens, M. A., Mulvey, C. K., Allen, G. M., SHIBOSKI, S. C., Rotow, J. K., Chakrabarti, T., Kerr, D. L., Aredo, J. V., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00071 · Cited by 78
Gong, Z., Du, M., Li, Y., Ye, B., Huang, Y., Gong, H., Wang, W., Chen, L., Ding, Z., & Zhang, P. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-02172-2 · Cited by 78
Pulmonary toxicity of immune checkpoint immunotherapy
Ghanbar, M., & Suresh, K. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170503 · Cited by 80
Lung Cancer in Women: The Past, Present, and Future
Florez, N., Kiel, L., Riaño, I., Patel, S. R., DeCarli, K., Dhawan, N., Franco, I., Odai-Afotey, A. A., Meza, K., Swami, N. S., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.10.007 · Cited by 77
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 80
Zhou, Q. H., Pan, Y., Yang, X., Zhao, Y., Han, G., Pang, Q., Zhang, Z., Wang, Q., Yao, J., Wang, H., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.024 · Cited by 71
Kim, S. S., Cooke, D. T., Kidane, B., Tapias, L. F., Lazar, J. F. L., Hayanga, J. W. A., Patel, J. D., Neal, J. W., Abazeed, M. E., Willers, H., et al. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.09.041 · Cited by 71
Wang, Z., Fan, J., Zhou, S., Sun, Y., Liang, F., Ji, Y., Gu, F., Li, T., Peng, L., Peng, T., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01720-9 · Cited by 72
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
Durbin, S., Zubiri, L., Perlman, K., Wu, C., Lim, T., Grealish, K., Hathaway, N., LoPiccolo, J., Wang, M., Falade, A. S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2668 · Cited by 69
Shang, X., Xie, Y., Yu, J., Zhang, C., Zhao, G., Liang, F., Liu, L., Zhang, W., Li, R., Yu, W., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.008 · Cited by 68
Zhou, Y., Li, A., Yu, H., Wang, Y., Zhang, X., Qiu, H., Du, W. T., Luo, L., Fu, S., Zhang, L., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1285 · Cited by 66
Abbosh, C., Hodgson, D., Doherty, G. J., Gale, D. G., Black, J. R., Horn, L., Reis-Filho, J. S., & Swanton, C. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.04.004 · Cited by 63
Houda, I., Bahce, I., Dickhoff, C., Kroese, T. E., Kroeze, S. G. C., Mariolo, A. V., Tagliamento, M., Moliner, L., Brandão, M., Pretzenbacher, Y., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108061 · Cited by 63
Management of Patients With Early-Stage Non-Small Cell Lung Cancer
Howington, J., Souter, L., Arenberg, D. A., Blasberg, J. D., Detterbeck, F. C., Farjah, F., Lanuti, M. D., Leighl, N. B., Videtic, G. M. M., & Murthy, S. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.06.023 · Cited by 62
Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 65
Zheng, Y., Liang, G., Yuan, D., Liu, X., Ba, Y., Qin, Z., Shen, S., Li, Z., Sun, H., Liu, B., et al. (2024) · 癌症：英文版 · doi:10.1002/cac2.12604 · Cited by 64
Spatially mapping the tumour immune microenvironments of non-small cell lung cancer
Desharnais, L., Sorin, M., Rezanejad, M., Liu, B., Karimi, E., Atallah, A., Swaby, A. M., Yu, M. W., Doré, S., Hartner, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56546-x · Cited by 60
Self-citationClinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Federico, A. D., Alden, S. L., Smithy, J. W., Ricciuti, B., Alessi, J. V., Wang, X., Pecci, F., Lamberti, G., Gandhi, M. M., Vaz, V. R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.06.014 · Cited by 57
Recent advances in lung cancer research: unravelling the future of treatment
Bertolaccini, L., Casiraghi, M., Uslenghi, C., Maiorca, S., & Spaggiari, L. (2024) · Updates in Surgery · doi:10.1007/s13304-024-01841-3 · Cited by 55
Lung cancer research and treatment: global perspectives and strategic calls to action
Meyer, M., Peters, S., Mok, T. S. K., Lam, S. C., Yang, P., Aggarwal, C., Brahmer, J. R., Dziadziuszko, R., Felip, E., Ferris, A. A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.10.006 · Cited by 55
Progress and challenges of artificial intelligence in lung cancer clinical translation
Zhu, E., Muneer, A., Zhang, J., Yang, X., Li, X., Zhou, C., Heymach, J. V., Wu, J., & Le, X. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00986-7 · Cited by 59
Recent advances and remaining challenges in lung cancer therapy
Barr, T., Ma, S., Li, Z., & Yu, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002991 · Cited by 52
Cascone, T., Bonanno, L., Guisier, F., Insa, A., Liberman, M., Bylicki, O., Livi, L., Egenod, T., Corre, R., Kim, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03746-z · Cited by 50
Self-citationIngels, J., Cock, L. D., Stevens, D., Mayer, R. L., Théry, F., Sanchez, G. S., Vermijlen, D., Weening, K., Smet, S. D., Lootens, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101516 · Cited by 49
Marinelli, D., Nuccio, A., Federico, A. D., Ambrosi, F., Bertoglio, P., Faccioli, E., Ferrara, R., Ferro, A., Giusti, R., Guerrera, F., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1443 · Cited by 48
Reck, M., Nadal, E., Girard, N., Filippi, A. R., Martin, L. W., Gay, C. M., Petersen, C., Gale, D. G., Emeribe, U. A., Georgoulia, N., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.06.007 · Cited by 47
Self-citationNeoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Awad, M. M., Forde, P. M., Girard, N., Spicer, J. D., Wang, C., Lü, S., Mitsudomi, T., Felip, E., Broderick, S., Swanson, S., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02239 · Cited by 47
Self-citationThe rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types
Awada, G., Cascone, T., van der Heijden, M. S., Blank, C. U., Kok, M., & Chalabi, M. (2025) · Nature Cancer · doi:10.1038/s43018-025-00990-7 · Cited by 51
Huang, S., Chung, J. Y., Li, C., Wu, Y., Qiao, G., To, K., & Tang, P. M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217272 · Cited by 49
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Zhou, L., Lu, Y., Liu, W., Wang, S., Wang, L., Zheng, P., Zi, G., Liu, H., Liu, W., & Wei, S. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00493-8 · Cited by 44
Patkar, S., Chen, A., Basnet, A., Bixby, A., Rajendran, R., Chernet, R., Faso, S., Kumar, P. A., Desai, D., El-Zammar, O., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00765-w · Cited by 41
“Although ICI-treatment is approved for the treatment of NSCLC patients in the localized andmetastaticsettingregardlessofPD-L1status 2 – 4 ,manypatientsstillfailto achieve clinically meaningful responses.”
Nuccio, A., Viscardi, G., Salomone, F., Servetto, A., Venanzi, F. M., Riva, S. T., Oresti, S., Ogliari, F. R., Viganò, M., Bulotta, A., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113404 · Cited by 41
The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives
Wisdom, A. J., Barker, C. A., Chang, J. Y., Demaria, S., Formenti, S. C., Grassberger, C., Gregucci, F., Hoppe, B. S., Kirsch, D. G., Marciscano, A. E. E., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.12.046 · Cited by 39
Ricciuti, B., Fusco, F., Cooper, A. J., Garbo, E., Pecci, F., Aldea, M. D., Wang, X., Mayoral, M., Ginsberg, M. S., Sholl, L. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.1115 · Cited by 39
Self-citationAdvances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives
Daste, A., Larroquette, M., Gibson, N., Lasserre, M., & Domblides, C. (2023) · Immunotherapy · doi:10.2217/imt-2023-0174 · Cited by 40
Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective
Houda, I., Dickhoff, C., Groot, C. A. U., Damhuis, R. A. M., Reguart, N., Provencio, M., Lévy, A., Dziadziuszko, R., Pompili, C., Maïo, M. D., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100841 · Cited by 41
Zhang, L., Qiu, M., Wang, R., Li, S., Liu, X., Xu, Q., Xiao, L. X., Jiang, Z., Zhou, X., & Chen, S. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202403771 · Cited by 38
Zhao, Z.-R., Liu, S., Zhou, T., Chen, G., Long, H., Su, X., Zhang, X., Fu, J., Lin, P., Zhang, L., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00215-7 · Cited by 38
Rapid Advances in Resectable Non–Small Cell Lung Cancer
West, H., & Kim, J. Y. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.5276 · Cited by 37
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Dunne, E. G., Fick, C. N., Isbell, J. M., Chaft, J. E., Altorki, N. K., Park, B. J., Spicer, J. D., Forde, P. M., Gomez, D. R., Iyengar, P., et al. (2024) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2024.01.024 · Cited by 38
Self-citationHouda, I., Dickhoff, C., Groot, C. A. U., Reguart, N., Provencio, M., Lévy, A., Dziadziuszko, R., Pompili, C., Maïo, M. D., Thomas, M., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100840 · Cited by 36
Xia, H., Zhang, H., Ruan, Z., Zhang, H., Sun, L., Chen, H., Zhou, Y., Zhang, L., Bian, D., Zhu, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01861-w · Cited by 36
Self-citationCurrent challenges and practical aspects of molecular pathology for non-small cell lung cancers
Hofman, P. M., Berezowska, S., Kazdal, D. N., Mograbi, B., Ilié, M., Stenzinger, A., & Hofman, V. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03651-1 · Cited by 36
Marinelli, D., Gallina, F. T., Pannunzio, S., Civita, M. A. D., Torchia, A., Giusti, R., Gelibter, A. J., Roberto, M., Verrico, M., Melis, E., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104190 · Cited by 35
Self-citationYang, Z., Wang, S., Yang, H., Jiang, Y., Zhu, L., Zheng, B., Fu, H., Ma, J., Xie, H., Wang, Z., et al. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.02.006 · Cited by 34
Self-citationElkrief, A., Routy, B., Derosa, L., Bolte, L. A., Wargo, J. A., McQuade, J. L., & Zitvogel, L. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-472902 · Cited by 36
Tertiary lymphoid structures: new immunotherapy biomarker
Yang, F., Yang, J., Wu, M., Chen, C. Y., & Chu, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1394505 · Cited by 33
Self-citationMitsudomi, T., Heymach, J. V., Reck, M., Taube, J. M., Gao, S., Horio, Y., You, J., Li, G., Luong, D. V., Saeteng, S., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.06.015 · Cited by 32
Self-citationTakada, K., Takamori, S., Brunetti, L., Crucitti, P., & Cortellini, A. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.017 · Cited by 29
Remón, J., Bortolot, M., Bironzo, P., Cortiula, F., Menis, J., Brandão, M., Naidoo, J., van Geel, R. M. J. M., Reguart, N., Arrieta, O. G., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02347 · Cited by 28
Neoadjuvant Immunotherapy: A Promising New Standard of Care
Boydell, E., Sandoval, J. L., Michielin, O. A., Obéid, M., Addeo, A., & Friedlaender, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411849 · Cited by 30
Soo, R. A., de Marinis, F., Han, J., Ho, J., Martin, E. C., Servidio, L., Sandelin, M., & Popat, S. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.09.005 · Cited by 28
Figueroa, P. U., Lacroix, V., & Schil, P. E. V. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.02.009 · Cited by 28
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
Lee, J. B., Choi, S., Shim, H. S., Park, B. J., Lee, C. Y., Sudhaman, S., Velichko, S., Hong, M. H., Cho, B. C., & Lim, S. M. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.023 · Cited by 27
Reprogramming cancer immunity with next-generation combination therapies
Kyriakidis, N. C., Echeverría, C. E., Bautista, J., Rivera-Orellana, S., Ramos-Medina, M. J., Salazar-Santoliva, C., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Guerrero, S. X., & López‐Cortés, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1652047 · Cited by 29
Wu, W., Liu, Q., An, P.-G., Wang, L., Zhang, J., Chen, Y., Zhang, T., & Zhang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1282629 · Cited by 27
Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
O’Leary, C. L., Pierce, N., Patel, S. P., & Naidoo, J. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.018 · Cited by 27
Parisi, C., Abdayem, P., Tagliamento, M., Besse, B., Planchard, D., Remón, J., Minuti, G., Cappuzzo, F., & Barlési, F. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102845 · Cited by 28
Metadata
- Authors
- Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., Martinengo, G. L., Bylicki, O., Rodríguez-Abreu, D., Chaft, J. E., Novello, S., Yang, J., Keller, S. M., Samkari, A., & Spicer, J. D.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- From Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA (H.W.); Centre Hospitalier de l’Université de Montréal (M.L.) and McGill University Health Centre (J.D.S.) — both in Montreal; Kanagawa Cancer Center, Yokohama (T.K.), and National Cancer Center Hospital East, Kashiwa (M.T.) — both in Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (S.-H.L.); the National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (S.G.), and Beijing Cancer Hospital, Peking University (K.-N.C.) — both in Beijing; University Hospitals Leuven, Leuven, Belgium (C.D.); Hospital de la Santa Creu i Sant Pau, Barcelona (M.M.), and Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas (D.R.-A.) — both in Spain; Zentralklinik Bad Berka, Bad Berka, Germany (E.E.); Sanatorio Parque, Cordoba, Argentina (G.L.M.); Hôpital d’I...
- Memorial Sloan Kettering Cancer Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 491-503
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11074923
- OpenAlex
- W4379209546
- Cited by
- 1,180
- References
- 18
- Citations by year
- 2026: 324 · 2025: 388 · 2024: 368 · 2023: 100
- FWCI
- 216.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Acceda (Universidad de Las Palmas de Gran Canaria) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Merck Sharp and Dohme LLC, a subsidiary of Merck & Co, Inc
- National Cancer Institute (P30 CA008748)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- pembrolizumab, early-stage non-small cell lung cancer, perioperative immunotherapy, PD-1 inhibitors, cisplatin-based chemotherapy, event-free survival, overall survival, pathological response, pathological complete response, N2 disease, resectable lung cancer, treatment safety, immune-related adverse events
- MeSH terms
- Adjuvants, Immunologic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Combined Modality Therapy, Humans, Lung Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
